Hepatitis-B virus infection in India: Findings from a nationally representative serosurvey, 2017-18

Manoj V Murhekar,Muthusamy Santhosh Kumar,P Kamaraj,Siraj Ahmed Khan,Ramesh Reddy Allam,Pradip Barde,Bhagirathi Dwibedi,Suman Kanungo,Uday Mohan,Suman Sundar Mohanty,Subarna Roy,Vivek Sagar,Deepali Savargaonkar,Babasaheb V Tandale,Roshan Kamal Topno,C P Girish Kumar,R Sabarinathan,Sailaja Bitragunta,Gagandeep Singh Grover,P V M Lakshmi,Chandra Mauli Mishra,Provash Sadhukhan,Prakash Kumar Sahoo,S K Singh,Chander Prakash Yadav,Rajesh Kumar,Shanta Dutta,G S Toteja,Nivedita Gupta,Sanjay M Mehendale,ICMR – Serosurvey group,T Karunakaran,Annamma Jose,D Augustine,C Govindhasamy,T Daniel Rajasekar,A Jeyakumar,A Suresh,P Ashok Kumar,R Sivakumar,J W Banerjee John
DOI: https://doi.org/10.1016/j.ijid.2020.08.084
Abstract:Introduction: India introduced a hepatitis-B (HB) vaccine in the Universal Immunization Program in 2002-2003 on a pilot basis, expanded to ten states in 2007-2008 (phase-1), and the entire country in 2011-2012 (phase-2). We tested sera from a nationally representative serosurvey conducted duing 2017, to estimate the seroprevalence of different markers of HB infection among children aged 5-17 years in India and to assess the impact of vaccination. Methods: We tested sera from 8273 children for different markers of HB infection and estimated weighted age-group specific seroprevalence of children who were chronically infected (HBsAg and anti-HBc positive), and immune due to past infection (anti-HBc positive and HBsAg negative), and having serological evidence of HB vaccination (only anti-HBs positive). We compared the prevalence of serological markers among children born before (aged 11-17 years) and after (aged 5-10 years) introduction of HB-vaccine from phase-1 states. Results: Among children aged 5-8 years, 1.1% were chronic carriers, 5.3% immune due to past infection, and 23.2% vaccinated. The corresponding proportions among children aged 9-17 years were 1.1%, 8.0%, and 12.0%, respectively. In phase-1 states, children aged 5-10 years had a significantly lower prevalence of anti-HBc (4.9% vs. 7.6%, p<0.001) and higher prevalence of anti-HBs (37.7% vs. 14.7%, p<0.001) compared to children aged 11-17 years. HBsAg positivity, however, was not different in the two age groups. Conclusions: Children born after the introduction of HB vaccination had a lower prevalence of past HBV infection and a higher prevalence of anti-HBs. The findings of our study could be considered as an interim assessment of the impact of the hepatitis B vaccine introduction in India.
What problem does this paper attempt to address?